PHC GROUPPHC Holdings Corporation

  • About Us
  • Group Companies
  • Products & Services
  • Sustainability
  • Investor Relations
  • Newsroom

About Us

About PHC GroupCEO MessageMission, Vision & ValuesValue Creation PlanHistory LeadershipPHC Group by the Numbers

Group Companies

Ascensia LSI Medience Wemex Mediford Epredia PHCbi PHC IVD

Products & Services

Cancer Pathology Biologic & Cell Preservation Diagnostic Testing Patient Record & Billing Software Diabetes Management Medical Device & Drug Delivery

Sustainability

Sustainability
  • CEO Message
  • Materiality
  • Sustainability Management
  • PHC GROUP Integrated Report
  • Environment image
    Environment
  • Society image
    Social
  • Governance image
    Governance

Investor Relations

INVESTOR RELATIONS

MANAGEMENT

  • Corporate Governance
  • IR Basic Policy
  • Business Risks

IR LIBRARY

  • Financial Results
  • Presentation Materials
  • IR Materials
  • Historical Financial Data
  • PHC GROUP Integrated Report
  • Mid-term Plan
  • Our Group Introduction

STOCK INFORMATION

  • Stock Overview
  • General Meeting of Shareholders
  • Shareholder Newsletter
  • Stock Quotations
  • Analyst Coverage
IR News Financial Highlights IR Calendar Contact IR Disclaimer

Newsroom

NEWSROOM

NEWS

  • PHC Holdings Corporation
  • PHC Group Companies
CareersContact
JP

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation
CareersContactJP
Newsroom > 2023 > LSI Medience Begins Contract Testing Service for GenMineTOP® Cancer Genome Profiling System

News


2023

NewsAugust 1, 2023

LSI Medience Begins Contract Testing Service for GenMineTOP® Cancer Genome Profiling System

LSI Medience Corporation (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director: Haruo Watanabe) announces an executed contract reflecting an agreement with Konica Minolta REALM, Inc. (headquarters: Minato-ku, Tokyo, Japan, President, Representative Director: Junji Tashiro, hereafter Konica Minolta REALM) to provide contract testing for the GenMineTOP® Cancer Genome Profiling System. Konica Minolta REALM began sales and contract testing services with medical institutions from August 1, 2023. For more information, please see the announcement made by Konica Minolta, Inc.

- For details on the contract testing:
www.medience.co.jp/clinical/information/ (only in Japanese)
- Announcement made by Konica Minolta, Inc.:
www.konicaminolta.com/jp-ja/newsroom/2023/0801-01-01.html (only in Japanese)

About LSI Medience

Established in 1975, LSI Medience Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523). It is dedicated to business across clinical testing, diagnostic reagents and instruments, and drug development support, and creates new solutions based on core analytical capabilities accumulated over the years in diverse testing services. LSI Medience Corporation contributes to the prevention, early detection, and treatment of diseases, as well as engage in supporting development of next-generation medical care, such as personalized medicine.
URL: www.medience.co.jp/english/

For enquiries:

LSI Medience Corporation
General Affairs/Legal Affairs/Intellectual Property Department
Public Relations, General Affairs Group
E-mail:NPA-LSIM-PR@nm.medience.co.jp

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
Terms of UsePrivacy PolicyFacebookLinkedIn © PHC Holdings Corporation All rights reserved.